Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2018 | Mogamulizumab: an exciting antibody for autoimmunity

Martine Bagot • 27 Sep 2018
EORTC CLTF 2018
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Antibodies Mogamulizumab

Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, discusses the exciting new approval of the antibody mogumulizumab for cutaneous T-cell lymphoma. Speaking at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, she presents two case studies of patients who developed autoimmunity, where they entered complete remission for a significant period of time after receiving injections of this antibody. Prof. Bagot is excited about the therapy and accounts the antibodies successful response to its potential mechanism of regulatory T-cell depletion.

More from Martine Bagot

1:05
Updates on the TELLOMAK trial
Martine Bagot • 15 Oct 2021
0:40
MAVORIC: long-term clinical benefit of mogamulizumab in patients with CTCL
Martine Bagot • 15 Oct 2021
0:54
Mogamulizumab-associated rash in CTCL
Martine Bagot • 15 Oct 2021
0:32
The future of CTCL therapy
Martine Bagot • 15 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals